Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-05-22 4:05 pm Purchase | 2023-05-12 | 13G | Recursion Pharmaceuticals, Inc. RXRX | Kinnevik AB (publ) | 10,405,668 5.600% | 10,405,668 (New Position) | Filing History |
| 2023-02-14 4:05 pm Sale | 2022-12-31 | 13G | Recursion Pharmaceuticals, Inc. RXRX | Lux Capital Management LLC | 6,004,722 3.300% | -7,016,797 (-53.89%) | Filing History |
| 2023-02-09 11:30 am Purchase | 2022-12-30 | 13G | Recursion Pharmaceuticals, Inc. RXRX | The Vanguard Group | 10,057,363 5.540% | 10,057,363 (New Position) | Filing History |
| 2023-02-03 12:10 pm Purchase | 2022-12-31 | 13G | Recursion Pharmaceuticals, Inc. RXRX | BlackRock Inc. BLK | 10,667,624 5.900% | 10,667,624 (New Position) | Filing History |
| 2023-01-24 07:35 am Purchase | 2022-12-30 | 13G | Recursion Pharmaceuticals, Inc. RXRX | BAILLIE GIFFORD & CO | 24,820,850 13.660% | 2,697,695 (+12.19%) | Filing History |
| 2022-10-31 4:08 pm Purchase | 2022-10-27 | 13D | Recursion Pharmaceuticals, Inc. RXRX | Mubadala Investment Co PJSC | 11,291,937 6.300% | 2,551,020 (+29.18%) | Filing History |
| 2022-02-14 4:16 pm Purchase | 2021-12-31 | 13G | Recursion Pharmaceuticals, Inc. RXRX | Lux Capital Management LLC | 13,021,519 8.200% | 13,021,519 (New Position) | Filing History |
| 2022-02-14 3:23 pm Purchase | 2021-12-31 | 13G | Recursion Pharmaceuticals, Inc. RXRX | Data Collective IV, L.P. | 13,619,224 8.500% | 13,619,224 (New Position) | Filing History |
| 2022-01-27 10:18 am Purchase | 2021-12-31 | 13G | Recursion Pharmaceuticals, Inc. RXRX | BAILLIE GIFFORD & CO | 22,123,155 13.870% | 5,104,498 (+29.99%) | Filing History |
| 2021-11-04 5:27 pm Unchanged | 2021-11-01 | 13D | Recursion Pharmaceuticals, Inc. RXRX | Mubadala Investment Co PJSC | 8,740,917 5.500% | 0 (Unchanged) | Filing History |
| 2021-05-06 12:01 pm Purchase | 2021-04-30 | 13G | Recursion Pharmaceuticals, Inc. RXRX | BAILLIE GIFFORD & CO | 17,018,657 10.890% | 17,018,657 (New Position) | Filing History |
| 2021-04-26 4:34 pm Purchase | 2021-04-16 | 13D | Recursion Pharmaceuticals, Inc. RXRX | Mubadala Investment Co PJSC | 8,740,917 5.700% | 8,740,917 (New Position) | Filing History |